fbpx
Andrew Civitello, MD

Dr. Andrew Civitello supports THI’s mission through his leadership as the Program Director of The Advanced Heart Failure and Transplant Cardiology Fellowship. Show full bio

Dr. Andrew Civitello is board-certified in Cardiology, Interventional Cardiology and Advanced Heart Failure and Transplant Cardiology and serves as the Medical Director of the Heart Transplant Program at The Texas Heart Institute as a member of the THI Professional Staff. He received his medical degree from The University of Texas Health Science Center in Houston. His extensive training includes internship, residency and a year as Chief Medical Resident at The University of Texas Health Science Center in Houston, followed by fellowships in Cardiology and Interventional Cardiology at Baylor College of Medicine and The Texas Heart Institute. Dr. Civitello specializes in interventional cardiology and peripheral vascular procedures, with advanced training in heart failure management and heart transplantation, general and interventional cardiology, including cardiac catheterization, CT angiography, nuclear cardiology, and advanced training in peripheral artery interventions. The major focus of Dr. Civitello’s clinical and research interests include advanced heart failure management, mechanical circulatory support, and heart transplantation. He has authored and co-authored numerous articles for major scientific journals and spoken professionally in both national and international forums.

See Publications

Texas Heart Institute Positions

  • Medical Director Heart Transplant Program, THI Leadership
  • Teaching Staff, Cardiovascular Disease Fellowship
  • Program Director, Advanced Heart Failure and Transplant Cardiology Fellowship
  • Teaching Staff, Interventional Cardiology Fellowship

Interests

  • Interventional Cardiology
  • Advanced Heart Failure
  • Mechanical Circulatory Support
  • Novel Treatments for Heart Failure

Education

  • Medical School:

    University of Texas Health Science Center Houston

  • Residency:

    University of Texas Health Science Center - Houston

  • Fellowships:

    Baylor College of Medicine

Academic & Clinical Affiliations

Certifications

  • American Board of Internal Medicine

Honors, Awards and Memberships

Publications

Civitello, A. and Nair, A. (2023). Simultaneous heart-kidney transplantation: balancing competing outcomes for transplant wait-listed patients. J Am Coll Cardiol 81, 741–742. https://doi.org/10.1016/j.jacc.2022.12.010.
Maitra, N. S., Dugger, S. J., Balachandran, I. C. et al. (2023). Impact of the 2018 UNOS heart transplant policy changes on patient outcomes. JACC Heart Fail, S2213-1779(23)00038–0. https://doi.org/10.1016/j.jchf.2023.01.009.
Civitello, A. B. and Rogers, J. G. (2023). Toward a self-actuating continuous flow ventricular assist device: the pudding is in the proof. ASAIO J 69, 59–60. https://doi.org/10.1097/MAT.0000000000001881.
Inchaustegui, C. A., Patel, A., Lamba, H. K. et al. (2022). Impact of time off anticoagulation in patients with continuous-flow left ventricular assist devices. J Artif Organs. https://doi.org/10.1007/s10047-022-01367-8.
Walther, C. P., Benoit, J. S., Lamba, H. K. et al. (2022). Distinctive kidney function trajectories following left ventricular assist device implantation. J Heart Lung Transplant, S1053-2498(22)02110–6. https://doi.org/10.1016/j.healun.2022.08.024.
Krittanawong, C., Rivera, M. R., Shaikh, P. et al. (2022). Key concepts surrounding cardiogenic shock. Curr Probl Cardiol, 101303. https://doi.org/10.1016/j.cpcardiol.2022.101303.
Walther, C. P., Civitello, A. B., Liao, K. K. et al. (2022). Nephrology considerations in the management of durable and temporary mechanical circulatory support. Kidney360 3, 569–579. https://doi.org/10.34067/KID.0003382021.
Lamba, H. K., Parikh, U. M., Vincent, J. et al. (2022). Preoperative hyponatremia and survival after left ventricular assist device implantation. Artif Organs. https://doi.org/10.1111/aor.14280.
Shah, S. J., Borlaug, B. A., Chung, E. S. et al. (2022). Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet, S0140-6736(22)00016–2. https://doi.org/10.1016/S0140-6736(22)00016-2.
Broda, C. R., Frankel, W. C., Nair, A. P. et al. (2022). Continuous-flow ventricular assist device support in adult congenital heart disease: A 15-year, multicenter experience of temporary and durable support. ASAIO J. Available at: https://doi.org/10.1097/MAT.0000000000001853.